POLYCOMPONENT VACCINE IMMUNOVAC-VP-4 AND IMMUNOTHERAPEUTIC CONCEPT OF ITS USE FOR THE PREVENTION AND TREATMENT OF DISEASES CAUSED BY OPPORTUNISTIC MICROORGANISMS

Abstract

Aim. Analysis of experimental data and results of long-term clinical studies of immunotherapeutic and prophylactic effectiveness of a polycomponent vaccine, Immunovac-VP-4. Materials and methods. Immunogenic strains of Staphylococcus aureus, Klebsiella pneumoniae, Proteus vulgaris, Escherichia coli, which antigens possessed broad intra — and interspecific cross-protective activity were selected to obtain the vaccine. Immunological parameters were determined using flow cytometry with the use of diagnostic monoclonal antibodies to cytokines, Toll-like receptors, surface molecules of dendritic cells and lymphocytes. The clinical effect of Immunovac-VP-4 was evaluated in chronic inflammatory and allergic diseases, as well as in the prevention of acute respiratory diseases (ARI) in children’s organized groups. Results. Immunovac-VP-4, protected the mice from infection caused by etiologically significant strains of bacteria and viruses, increased TLR-2, 4, 9-expressing cells; maturing the dendritic cells; the synthesis of cytokines IL1β, IL-6, IL-10, IL-12, IFNγ,; proliferation and increased cytotoxicity of NK cells. Significant clinical effect (69.2 — 100)% of Immunovac-VP-4 on the background of the basic therapy was obtained in patients with chronic inflammatory and allergic diseases. The therapeutic effect was accompanied by a positive dynamics of immunological parameters, in particular, an increase in IFNγ and a decrease in IL-4. Immunotherapy and immunoprophylaxis using Immunovac-VP-4 led to a decrease in the number of episodes of acute respiratory infections and their bacterial complications, including children in organized groups. Conclusion. Immunological feasibility of using Immunovac-VP-4 in complex treatment and prevention of bacterial and viral infections, caused by opportunistic microorganisms, as well as in allergic diseases was proved.

Keywords

• immunovac-vp-4
• opportunistic microorganisms
• immunotherapy
• immunization
• innate immunity